Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 457
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2010, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials includes:

Trends in infectious vaccines dealmaking in the biopharma industry since 2010

Analysis of infectious vaccines deal structure

Access to headline, upfront, milestone and royalty data

Access to over 600 infectious vaccines deal records

Identify the most active infectious vaccine dealmakers since 2010

The leading infectious vaccines deals by value since 2010

Includes adjuvant deals and alliances since 2010

In Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 500 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of infectious vaccines deal trends since 2010

Access infectious vaccines deal headline, upfront, milestone and royalty data

Analysis of the structure of infectious vaccines agreements with numerous real life case studies

Comprehensive access to over 600 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples

Identify leading infectious vaccines deals by value since 2010

Identify the most active infectious vaccines dealmakers since 2010

Insight into the terms included in infectious vaccines agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2017: Deal trends, players and financials

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking
2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Most active Infectious Vaccines dealmakers
2.4. Infectious Vaccines partnering by deal type
2.5. Infectious Vaccines partnering by therapy area
2.6. Deal terms for Infectious Vaccines partnering
2.6.1 Infectious Vaccines partnering headline values
2.6.2 Infectious Vaccines deal upfront payments
2.6.3 Infectious Vaccines deal milestone payments
2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals
3.1. Introduction
3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers
4.1. Introduction
4.2. Most active Infectious Vaccines dealmakers
4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory
5.1. Introduction
5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Infectious Vaccines deals by company A-Z
Appendix 2 - Infectious Vaccines deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Infectious Vaccines deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 - Infectious Vaccines deals by therapy area
Appendix 5 - Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Infectious Vaccines partnering since 2010
Figure 2: Active Infectious Vaccines dealmaking activity since 2010
Figure 3: Infectious Vaccines partnering by deal type since 2010
Figure 4: Infectious Vaccines partnering by disease type since 2010
Figure 5: Infectious Vaccines deals with a headline value
Figure 6: Infectious Vaccines deals with an upfront value
Figure 7: Infectious Vaccines deals with a milestone value
Figure 8: Infectious Vaccines deals with a royalty rate value
Figure 9: Top Infectious Vaccines deals by value since 2010
Figure 10: Most active Infectious Vaccines dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Global Amoxicillin Market Professional Survey Report 2017
    Published: 09-Aug-2017        Price: US 3500 Onwards        Pages: 110
    This report studies Amoxicillin in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Eli Lilly and Company - Merck - Antibioticos - Sandoz - GSK......
  • Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2017
    Published: 08-Aug-2017        Price: US 2000 Onwards        Pages: 45
    Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 2017, provides an overview of the Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline landscape. Shigella Infections (Shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramp......
  • Osteomyelitis - Pipeline Review, H2 2017
    Published: 08-Aug-2017        Price: US 2000 Onwards        Pages: 47
    Osteomyelitis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis - Pipeline Review, H2 2017, provides an overview of the Osteomyelitis (Infectious Disease) pipeline landscape. Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, s......
  • Coccidioidomycosis - Pipeline Review, H2 2017
    Published: 08-Aug-2017        Price: US 2000 Onwards        Pages: 43
    Coccidioidomycosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coccidioidomycosis - Pipeline Review, H2 2017, provides an overview of the Coccidioidomycosis (Infectious Disease) pipeline landscape. Coccidioidomycosis, also called Valley fever, is an infection caused by the fungus Coccidioides. Symptoms include fever, cough, chest pain, chills, headache, fatigue and joint aches. R......
  • Cryptococcosis - Pipeline Review, H2 2017
    Published: 08-Aug-2017        Price: US 2000 Onwards        Pages: 34
    Cryptococcosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cryptococcosis - Pipeline Review, H2 2017, provides an overview of the Cryptococcosis (Infectious Disease) pipeline landscape. Cryptococcosis is infection caused by Cryptococcus neoformans fungus. Symptoms include cough, fatigue, fever, head ache, nausea and skin rashes. Predisposing factors are most often seen in people ......
  • United States Cephalosporin Drugs Market Report 2017
    Published: 31-Jul-2017        Price: US 3800 Onwards        Pages: 107
    In this report, the United States Cephalosporin Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate......
  • Global Antibiotics Market Research Report 2017-2022 By Players, Regions, Product Types & Applications
    Published: 31-Jul-2017        Price: US 2380 Onwards        Pages: 129
    The global Antibiotics market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. This report offers an overview of the market trends, drivers, and barriers with respect to the Antibiotics market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Antibiotics market by P......
  • Sinusitis - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Sinusitis -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Sinusitis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Sinusitis. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Sinusitis. The report contains the targeted patient populations and the forecast methodolog......
  • Shigella Infections - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 28-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Shigella Infections - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Shigella Infections for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Shigella Infections . It enables understanding......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs